Syntermed anticipates NeuroQ approval

Article

A software platform consisting of quantitative tools for the analysis of brain PET scans has just been submitted to the FDA, but its maker, Syntermed, is already looking forward to marketing the product. The company expects commercial release in the

A software platform consisting of quantitative tools for the analysis of brain PET scans has just been submitted to the FDA, but its maker, Syntermed, is already looking forward to marketing the product. The company expects commercial release in the third quarter for the NeuroQ software, which rapidly and automatically quantifies more than 200 standardized regions of interest. It compares activity in those brain regions to regional activity values derived from a database of normal scans.

Related Videos
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Emerging Innovations in Molecular Imaging
Related Content
© 2023 MJH Life Sciences

All rights reserved.